Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks

Vipul Jain(McMaster University), Sibylle Haemmerle(Novartis (Switzerland)), Swapnil Dahale(IQVIA (India)), Adam Reich(Rzeszów University of Technology), Koremasa Hayama(Nihon University), Artem Zharkov(Novartis (Switzerland)), Sophie Hugot(Novartis (Switzerland)), Ana M. Giménez‐Arnau(Universitat Autònoma de Barcelona), Warner Carr(Asthma Association), Jeffrey Tillinghast(Orthopedic Center), K. Lheritier(Novartis (Switzerland)), Pauline Walsh(Novartis (Ireland))
Journal of Allergy and Clinical Immunology
October 20, 2023
10.1016/j.jaci.2023.10.007
Cited by 71

Related Papers

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
|Acta Dermato Venereologica|2012|579
Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
|Acta Dermato Venereologica|2012|502